Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Dynavax Technologies (NQ: DVAX )

9.070 USD +0.190 (+2.14%)
Streaming Delayed Price Updated: 9:42 AM EDT, May 7, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 252,918
Open 9.090
Bid (Size) 9.060 (3)
Ask (Size) 9.080 (1)
Prev. Close 8.880
Today's Range 8.990 - 9.290
52wk Range 3.550 - 12.44
Shares Outstanding 114,588,212
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Dynavax Announces First Quarter 2021 Financial Results
- First quarter 2021 total revenue of $83.3 million, driven by strong execution in the CpG 1018 adjuvant business 
From PR Newswire
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 148,500 shares of Dynavax common stock as inducements to seven... 
From PR Newswire

Performance

YTD
+96.32%
+96.32%
1 Month
-10.38%
-10.38%
3 Month
-5.42%
-5.42%
6 Month
+119.61%
+119.61%
1 Year
+94.64%
+94.64%

More News

Read More
HEPLISAV-B Post-Marketing Observational Study Results Presented at 2021 Annual Conference on Vaccinology Research (ACVR)
From PR Newswire
Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
From PR Newswire
Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax's CpG 1018™ Adjuvant
From PR Newswire
Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
From GlobeNewswire News Releases
Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
From GlobeNewswire News Releases
The Importance of Alternative Healthcare Options Grows in the Midst of the Pandemic
From PR Newswire
Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR)
From PR Newswire
Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant
From PR Newswire
How Dynavax Demolished Expectations With Its Q1 Results
Tags Market News DVAX
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.